Investment Thesis
Coya Therapeutics is a pre-commercial biotech company burning $6.2M annually while generating only $251K in revenue, indicating it is in early development stages with uncertain commercialization prospects. While the strong cash position ($50.7M) and zero debt provide operational runway (~8 years at current burn), the lack of revenue traction, flat year-over-year net losses, and deteriorating EPS (-29.6% YoY) suggest execution challenges and elevated risk of shareholder dilution through future capital raises.
Strengths
- Substantial cash position of $50.7M (95% of total assets) provides multi-year operational runway
- Zero debt with clean balance sheet (0.00x debt-to-equity ratio)
- Strong liquidity metrics (15.02x current ratio) enable extended investment in R&D without near-term bankruptcy risk
- Revenue growth of 123.6% YoY, though from minimal base of $251K
Risks
- Massive operating losses of $7.6M against revenue of $251K indicate unsustainable unit economics and pre-commercial stage
- Negative free cash flow of $6.2M annually with no clear path to profitability in visible metrics
- Net income flat year-over-year ($0.0% change) suggests no improvement in loss trajectory despite size
- EPS deteriorating at -29.6% YoY indicates worsening per-share performance
- Minimal insider activity (1 Form 4 filing in 90 days) suggests low insider confidence in near-term execution
- Pharmaceutical sector requires successful clinical development and regulatory approval—inherent binary risk of failure
Key Metrics to Watch
- Operating cash flow trajectory and cash runway calculation
- Revenue growth rate and path to gross margin positivity
- Clinical trial progress, regulatory milestones, and FDA interactions
- Operating expense burn rate reduction or stabilization
- Insider transaction activity and equity dilution from future fundraising rounds
Financial Metrics
Revenue
251.1K
Net Income
-7.2M
EPS (Diluted)
$-0.32
Free Cash Flow
-6.2M
Total Assets
53.3M
Cash
50.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,042.1%
Net Margin
-2,869.6%
ROE
-14.7%
ROA
-13.5%
FCF Margin
-2,472.1%
Balance Sheet & Liquidity
Current Ratio
15.02x
Quick Ratio
15.02x
Debt/Equity
0.00x
Debt/Assets
8.1%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:07:46.044892 |
Data as of: 2026-03-31 |
Powered by Claude AI